The Sepsis Diagnostics Market is expanding as hospitals, diagnostic laboratories, and healthcare organizations strengthen their ability to identify serious infections at an early stage. Growing awareness of sepsis, increasing healthcare-associated infections, and the need for rapid clinical decision-making are creating sustained demand for advanced diagnostic solutions.

Market Research Future estimates that the global market reached USD 0.85 billion in 2025 and will grow from USD 0.91 billion in 2026 to USD 1.69 billion by 2035. The market is expected to register a CAGR of 7.1% over the 2026–2035 forecast period.

One of the most important market drivers is the global burden of sepsis. According to information presented in the report, the Global Burden of Disease Study estimated 48.9 million sepsis cases and 11 million sepsis-related deaths in 2017. This substantial disease burden creates an ongoing requirement for diagnostic testing and monitoring.

Hospital-acquired infections are another important factor. Healthcare facilities must identify infectious organisms rapidly to support infection control and appropriate antimicrobial treatment. Diagnostic technologies that provide faster pathogen identification can help hospitals improve workflow and support antimicrobial stewardship initiatives.

Regulatory and reimbursement requirements are also contributing to demand. In the United States, the CMS SEP-1 measure has encouraged hospitals to follow standardized sepsis-management protocols. Such requirements increase the importance of timely blood cultures, laboratory testing, and clinical assessment. Similar healthcare-quality initiatives in other regions are supporting greater attention to sepsis diagnosis.

The product landscape includes instruments, blood culture media, assay kits and reagents, and software. Assays and reagents held approximately 52% of the market in 2025, supported by recurring procurement requirements.

North America is currently the largest regional market, accounting for approximately 38% share. The region benefits from sophisticated hospital infrastructure, established diagnostic laboratories, and strong adoption of advanced testing technologies. Europe represents approximately 29% of the market, while Asia-Pacific is expected to record the fastest growth, supported by healthcare investment and expanding diagnostic infrastructure.

The future of the market will increasingly depend on technologies that combine speed, accuracy, automation, and clinical usefulness. Point-of-care testing, molecular panels, biomarkers, artificial intelligence, and integrated laboratory platforms are expected to remain important areas of innovation.

As healthcare providers continue prioritizing early diagnosis and appropriate treatment, the Sepsis Diagnostics Market is positioned for continued development. Greater accessibility to advanced diagnostic systems could help healthcare facilities improve sepsis recognition and strengthen patient management worldwide.